Real-World Use of Semaglutide for Weight Management: Dose Titration, Discontinuation Patterns and Weight Changes
Patients treated with semaglutide in real-world practice achieved meaningful weight loss despite using lower doses than clinical trial protocols.
In a Danish primary care practice, 38% of 206 semaglutide-treated patients permanently discontinued and 15% paused by 12 months, with 40% of remainers using doses lower than approved labeling. Despite slower titration and more discontinuation than clinical trials, patients who persisted achieved clinically meaningful -13.6% mean weight loss at 12 months.
What the study was
- Study design
- retrospective_observational_single_practice
- Category
- cardiovascular_metabolic
- Maturity
- Validated
- Journal
- Diabetes Obes Metab
Why it surfaced
Real-world adherence and effectiveness data confirming high semaglutide discontinuation (53%) and dose under-titration (40%) versus trial conditions; clinically important for prescribing expectations, but limited by single-practice n=206 design.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.